

Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis

Megan Barber¹, John G. Hanly², Aidan O'Keefe³, Li Su⁴, Murray Urowitz^{5,6}, Yvan St. Pierre⁷, Juanita Romero-Diaz⁸, C. Gordon⁹, Sang-Cheol Bae¹⁰, Sasha Bernatsky¹¹, Daniel J Wallace¹², Joan T. Merrill¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Ellen M. Ginzler¹⁶, Paul R. Fortin¹⁷, Dafna D. Gladman¹⁸, Jorge Sanchez-Guerrero¹⁹, Michelle Petri²⁰, Ian N. Bruce²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Cynthia Aranow²⁴, Graciela S. Alarcon²⁵, W. Winn Chatham²⁶, Kristján Steinsson²⁷, Ola Nived²⁸, Gunnar K. Sturfelt²⁹, Susan Manzi³⁰, Munther Khamashta³¹, Ronald F. van Vollenhoven³², Asad Zoma³³, Manel Ramos-Casals³⁴, Guillermo Ruiz-Irastorza³⁵, S. Sam Lim³⁶, Thomas Stoll³⁷, Murat Inanc³⁸, Kenneth C. Kalunian³⁹, Diane L. Kamen⁴⁰, Peter Maddison⁴¹, Christine A. Peschken⁴², Søren Jacobsen⁴³, Anca Askanase⁴⁴, Jill P. Buyon⁴⁵, Chris Theriault⁴⁶, Kara Thompson⁴⁶, Vernon Farewell⁴⁷ and **Ann E. Clarke**⁴⁸, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Statistical Science, University College London, London, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico, ⁹School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁵Centre for Rheumatology Research, Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁶Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁷Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁸Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²⁰Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²²UNC Kidney Centre, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Feinstein Institute for Medical Research, Mahasset, NY, ²⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁶Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁷Centre for Rheumatology Research, Landspítali University Hospital, Reykjavik, Iceland, ²⁸Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁰Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³¹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm,

Sweden, ³³Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Autoimmune Disease Research Unit, Service of Internal Medicine, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, ³⁶Emory University School of Medicine, Atlanta, GA, ³⁷Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ⁴⁰Medicine, Medical University of South Carolina, Charleston, SC, ⁴¹Musculoskeletal Medicine, Bangor University, Bangor, United Kingdom, ⁴²Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴³Department of Rheumatology,, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴⁶Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Economics, Health care cost, lupus nephritis and outcomes

SESSION INFORMATION

Date: Sunday, November 8, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and without LN.

Methods:

Patients from 32 centres in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, dialysis, and utilization of medications and selected procedures. LN was diagnosed by renal biopsy or fulfillment of the American College of Rheumatology (ACR) SLE classification criteria renal item. Renal function was also assessed annually based on estimated glomerular filtration rate (eGFR) or proteinuria (ePrU). Annual health resource utilization was costed using 2012 Canadian prices. Annual costs associated with renal function states were obtained from multiple regressions adjusting for age, race/ethnicity, disease duration, SLICC centre location, SLEDAI-2K and SLICC/ACR Damage Index (excluding renal components), and the SF-36. 5-year cumulative costs were estimated by determining annual costs associated with each renal function state and then forecasting the expected duration in each state. Durations were estimated using a relative risk regression model.

Results:

1645 patients participated, 89.2% females, 48.8% Caucasian, mean age at diagnosis 34.8 years (SD 13.4), mean disease duration at enrollment 0.5 years (SD 0.3), and mean follow up 6.1 years (SD 3.3). LN was diagnosed in 39.4% over follow up. Health resource utilization and annual costs (after adjustment using regression) were markedly higher in those with an eGFR < 30 ml/min or with LN (Table 1).

Table 1. Predicted Annual Health Costs Stratified by State of Renal Function					
eGFR		ePrU		Lupus Nephritis	
State	Costs, Mean 95% CI 2012 CDN\$	State	Costs, Mean 95% CI 2012 CDN\$	State	Costs, Mean 95% CI 2012 CDN\$
eGFR >60 ml/min	2234 (1503, 2965)	ePrU < 0.25g/d	2247 (1406, 3088)	No Lupus Nephritis	1588 (726,2450)
eGFR 30-60ml/min	3014 (1636, 4392)	ePrU 0.25-3.0g/d	3424 (2287, 4561)	Lupus Nephritis	3876 (2949,4803)
eGFR < 30 ml/min	12551 (10301, 14801)	ePrU > 3.0 g/d	4703 (2128, 7278)		

5-year cumulative costs stratified by baseline renal function state were calculated by multiplying the annual costs associated with each state by the expected duration in that state (eGFR example in Table 2).

Table 2. Expected Duration in Each Renal State over 5 Years				
Baseline State	Annual Costs 2012 CDN\$	Expected Duration in each State over 5 years		
		eGFR >60 ml/min	eGFR 30-60 ml/min	eGFR < 30 ml/min
eGFR >60 ml/min	2234	4.74 yrs	0.22 yrs	0.04 yrs

eGFR 30-60 ml/min	3014	2.60 yrs	1.88 yrs	0.52 yrs
eGFR < 30 ml/min	12551	1.03 yrs	1.09 yrs	2.88 yrs

Five year cumulative costs were greater in those with severely impaired eGFR or with LN at baseline (Table 3).

Table 3. Predicted 5-Year Cumulative Health Costs Stratified by Baseline State of Renal Function					
eGFR		ePrU		Lupus Nephritis	
Baseline State	Costs, Mean 95% CI 2012 CDN\$	Baseline State	Costs, Mean 95% CI 2012 CDN\$	Baseline State	Costs, Mean 95% CI 2012 CDN\$
eGFR >60 ml/ min	11763 (7904, 15622)	ePrU < 0.25 g/d	12070 (7594, 16547)	No Lupus Nephritis	8663 (4331, 12995)
eGFR 30-60 ml/min	18008 (12348, 23667)	ePrU 0.25-3.0 g/d	13834 (8758, 18909)	Lupus Nephritis	19380 (14745, 24015)
eGFR < 30 ml/min	41732 (32998, 50467)	ePrU > 3.0 g/d	15627 (9192, 22061)		

Conclusion:

Patients with an eGFR <30ml/min and LN incur higher annual and 5-year cumulative costs. By estimating the expected duration in each renal function state and incorporating associated annual costs, disease severity at presentation can be used to anticipate future healthcare costs, critical knowledge for cost effectiveness evaluations of novel LN therapies.

Disclosure: M. Barber, Bristol-Myers Squibb, 2; J. G. Hanly, Bristol-Myers Squibb, 2; A. O'Keefe, Bristol-Myers Squibb, 2; L. Su, Bristol-Myers Squibb, 2; M. Urowitz, Bristol-Myers Squibb, 2; Y. St.

Pierre, Bristol-Myers Squibb, 2; **J. Romero-Diaz**, Bristol-Myers Squibb, 2; **C. Gordon**, Bristol-Myers Squibb, 2; **S. C. Bae**, Bristol-Myers Squibb, 2; **S. Bernatsky**, Bristol-Myers Squibb, 2; **D. J. Wallace**, Bristol-Myers Squibb, 2; **J. T. Merrill**, Bristol-Myers Squibb, 2; **D. A. Isenberg**, Bristol-Myers Squibb, 2; **A. Rahman**, Bristol-Myers Squibb, 2; **E. M. Ginzler**, Bristol-Myers Squibb, 2; **P. R. Fortin**, Bristol-Myers Squibb, 2; **D. D. Gladman**, Bristol-Myers Squibb, 2; **J. Sanchez-Guerrero**, Bristol-Myers Squibb, 2; **M. Petri**, Bristol-Myers Squibb, 2; **I. N. Bruce**, Bristol-Myers Squibb, 2; **M. A. Dooley**, Bristol-Myers Squibb, 2; **R. Ramsey-Goldman**, Bristol-Myers Squibb, 2; **C. Aranow**, Bristol-Myers Squibb, 2; **G. S. Alarcon**, Bristol-Myers Squibb, 2; **W. W. Chatham**, Bristol-Myers Squibb, 2; **K. Steinsson**, Bristol-Myers Squibb, 2; **O. Nived**, Bristol-Myers Squibb, 2; **G. K. Sturfelt**, Bristol-Myers Squibb, 2; **S. Manzi**, Bristol-Myers Squibb, 2; **M. Khamashta**, Bristol-Myers Squibb, 2; **R. F. van Vollenhoven**, Bristol-Myers Squibb, 2; **A. Zoma**, Bristol-Myers Squibb, 2; **M. Ramos-Casals**, Bristol-Myers Squibb, 2; **G. Ruiz-Irastorza**, Bristol-Myers Squibb, 2; **S. S. Lim**, Bristol-Myers Squibb, 2; **T. Stoll**, Bristol-Myers Squibb, 2; **M. Inanc**, Bristol-Myers Squibb, 2; **K. C. Kalunian**, Bristol-Myers Squibb, 2; **D. L. Kamen**, Bristol-Myers Squibb, 2; **P. Maddison**, Bristol-Myers Squibb, 2; **C. A. Peschken**, Bristol-Myers Squibb, 2; **S. Jacobsen**, Bristol-Myers Squibb, 2; **A. Askanase**, Bristol-Myers Squibb, 2; **J. P. Buyon**, Bristol-Myers Squibb, 2; **C. Theriault**, Bristol-Myers Squibb, 2; **K. Thompson**, Bristol-Myers Squibb, 2; **V. Farewell**, Bristol-Myers Squibb, 2; **A. E. Clarke**, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Barber M, Hanly JG, O'Keefe A, Su L, Urowitz M, St. Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin PR, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcon GS, Chatham WW, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta M, van Vollenhoven RF, Zoma A, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Buyon JP, Theriault C, Thompson K, Farewell V, Clarke AE. Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis [abstract]. *Arthritis Rheumatol*. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/economic-evaluation-of-lupus-nephritis-in-an-international-inception-cohort-comparing-the-hospitalization-medication-dialysis-and-procedure-costs-of-those-with-and-without-nephritis/>. Accessed January 17, 2017.

ACR Meeting Abstracts - <http://acrabstracts.org/abstract/economic-evaluation-of-lupus-nephritis-in-an-international-inception-cohort-comparing-the-hospitalization-medication-dialysis-and-procedure-costs-of-those-with-and-without-nephritis/>